Beckman Must Boost Lab Device Quality Practices: FDA

By Martin Bricketto (August 23, 2011, 3:18 PM EDT) -- The U.S. Food and Drug Administration has accused lab equipment maker Beckman Coulter Genomics Inc. of inadequate design validation and corrective and preventive action violations based on an investigation at the company's Brea, Calif., facility, according to a warning letter released Tuesday.

The FDA's Aug. 9 warning letter to the company, which was recently acquired by Danaher Corp., concerns Beckman Coulter's diagnostic chemistry analyzers, reagents, calibrators and controls.

A federal inspection of the facility between March and May revealed that, in some cases, methods, facilities or controls associated with the devices failed to conform to current good manufacturing practice requirements under...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!